TokenPost topic

Maze Therapeutics

1 TokenPost story is tagged Maze Therapeutics. The newest appear first.

Latest Maze Therapeutics stories

• Maze Therapeutics Posts $0.79 Q3 GAAP Loss Per Share as R&D Costs Rise

  Net loss reached $48 million. Cash, cash equivalents and marketable securities totaled $477 million on Sept. 30, 2026.

  Nov 11, 2026, 5:52 AM EST · Business